NIAID Advanced Technology STTR (NIAID-AT-STTR [R41/R42])

The summary for the NIAID Advanced Technology STTR (NIAID-AT-STTR [R41/R42]) Federal Grant is detailed below. It contains information such as the Catalog of Federal Domestic Assistance (CFDA) number, who is eligible for the grant, how much grant money will be awarded, important deadlines, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed in the Grant Announcement Contact section. If these sections are incomplete, please visit the website of the government agency that is offering this grant.


	Federal Grant Title:	NIAID Advanced Technology STTR (NIAID-AT-STTR [R41/R42])
	CFDA Number:	93.855
	CFDA Description:	Allergy, Immunology and Transplantation Research
	Federal Agency Name:	National Institutes of Health
	Category of Funding Activity:	Health
	Category Explanation:	Information not provided
	Opportunity Category:	Discretionary
	Funding Opportunity Number:	PA-10-124
	Document Type:	Grants Notice
	Funding Instrument Type:	Grant
	Posted Date:	Mar 05, 2010
	Creation Date:	Mar 05, 2010
	Original Closing Date for Applications:	Jan 07, 2013
	Current Closing Date for Applications:	Jan 07, 2013
	Archive Date:	Feb 07, 2013
	Expected Number of Awards:	Information not provided
	Estimated Total Program Funding:	Information not provided
	Federal Grant Award Ceiling:	Information not provided
	Federal Grant Award Floor:	Information not provided
	Cost Sharing or Matching Requirement:	No

Applicants Eligible for this Grant: Small businesses
Additional Information on Eligibility: Information not provided
Grant Description: Purpose. Add This funding opportunity announcement (FOA) encourages Small Business Technology Transfer Research (STTR) grant applications from small business concerns (SBCs) for advanced technology projects that require a longer award period and greater award amount than those routinely allowed under the SBIR program. For this FOA, "advanced technology" is defined as a clearly identified product or service that requires approval of the Food and Drug Administration (FDA) and is within the mission of NIAID. An example of a clearly identified product is a research project focused on a lead compound for an AIDS drug. A research project focused on developing an assay to identify lead compounds does not have a clearly identified product and would not be appropriate for this FOA. Only applications meeting the above advanced technology definition should be submitted in response to this FOA. Applications in response to this FOA should not contain human clinical trials. NIAID Policy currently only allows investigator initiated clinical trials to be submitted using the R34 mechanism. Information on this process can be found at the following site: http://funding.niaid.nih.gov/ncn/clinical/R34.htm. Mechanism of Support. This FOA will utilize the STTR (R41/R42) grant mechanisms for Phase I, Phase II, and and Fast-Track and runs in parallel with a FOA of identical scientific scope, PA-10-123, that encourages applications under the Small Business Innovation Research (SBIR) (R43/R44) grant mechanisms. Funds Available and Anticipated Number of Awards. Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications. The total amount awarded and the number of awards will depend upon the quality, duration, and costs of the applications received.
Link to Full Grant Announcement: http://grants.nih.gov/grants/guide/pa-files/pa-10-124.html
Grant Announcement Contact: NIH OER WebmasterFBOWebmaster@OD.NIH.GOV
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster [FBOWebmaster@OD.NIH.GOV]
Similar Government Grants: • Innovation for HIV Vaccine Discovery (R01); • NIAID Clinical Trial Implementation Cooperative Agreement (U01); • Therapeutics for Neurotropic Biodefense Toxins and Pathogens (R21/R33); • Strategies for the Protection of Pregnant Women and Infants Against Infectious Diseases (R01); • Predictive Biodosimetry: Discovery and Development of Biomarkers for Acute and Delayed Radiation Inj...; • Center for HIV/AIDS Vaccine Immunology (CHAVI); • Genomics of Transplantation Cooperative Research Program; • Asthma and Allergic Diseases Cooperative Research Centers; • Radionuclide Decorporation Agents for Radiation/Nuclear Emergencies: Project BioShield (R01); • Asthma and Allergic Diseases Cooperative Research Centers (U19)